Royalmount Biopharma Services (RBS), a division of Pharmascience, is a Canadian leader in pharmaceutical development with two units: CDMO and Laboratory Services. For over 30 years, our labs have provided GLP-accredited, GMP-compliant bioanalytical services for preclinical and clinical studies using LC-MS/MS, ELISA, qPCR, and Luminex. We analyze small molecules, peptides, proteins, oligonucleotides, RNA, and biotherapeutics across diverse matrices, meeting Health Canada, EMA, and FDA standards. Our FDA-approved CDMO facility in Candiac offers drug development and manufacturing for small and large molecules, including oligonucleotides, mAbs, and ADCs, with cytotoxic capabilities for vials, syringes, and lyophilized products. Through partnerships, we support preclinical studies and Phase I–III trials. As part of Pharmascience, RBS combines scientific excellence and regulatory expertise to guide biopharma partners from early development to commercial production.